1Kilaru A, Blancaflor EB, Venables BJ, et al. (2007) The N-acylethanolamine-mediated regulatory pathway in plants. Chem Biodivers 4, 1933–1955.
2Okamoto Y, Wang J, Morishita J, et al. (2007) Biosynthetic pathways of the endocannabinoid anandamide. Chem Biodivers 4, 1842–1857.
3Borrelli F & Izzo AA (2009) Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Prac Res Clin Endocrinol Metab 23, 33–49.
4Alexander SPH & Kendall DA (2007) The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 152, 602–623.
5Di Marzo V, Bisogno T & De Petrocellis L (2007) Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol 14, 741–756.
6Re G, Barbero R, Miolo A, et al. (2007) Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 173, 21–30.
7Hoareau L, Buyse M, Festy F, et al. (2009) Anti-inflammatory effect of palmitoylethanolamide on human adipocytes. Obesity 17, 431–438.
8Thabuis C, Tissot-Favre D, Bezelgues JB, et al. (2008) Biological functions and metabolism of oleoylethanolamide. Lipids 43, 887–894.
9Schwartz GJ, Fu J, Astarita G, et al. (2008) The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 8, 281–288.
10Terrazzino S, Berto F, Carbonare MD, et al. (2004) Stearoylethanolamide exerts anorexic effects in mice via down-regulation of liver stearoyl-coenzyme A desaturase-1 mRNA expression. FASEB J 18, 1580–1582.
11Dalle Carbonare M, Del Giudice E, Stecca A, et al. (2008) A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: a neglected story. J Neuroendocrinol 20, 26–34.
12Burstein S (2008) The elmiric acids: biologically active anandamide analogs. Neuropharmacology 55, 1259–1264.
13Burstein SH & Zurier RB (2009) Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 11, 109–119.
14Calder PC (2007) Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 77, 327–335.
15Calder PC (2008) The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot Essent Fatty Acids 79, 101–108.
16Harris WS (2008) n-3 Fatty acids and health: DaVinci's code. Am J Clin Nutr 88, 595–596.
17Harris WS & Bulchandani D (2006) Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 17, 387–393.
18Russo GL (2009) Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 77, 937–946.
19Artmann A, Petersen G, Hellgren LI, et al. (2008) Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 1781, 200–212.
20Berger A, Crozier G, Bisogno T, et al. (2001) Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A 98, 6402–6406.
21Bisogno T, Delton-Vandenbroucke I, Milone A, et al. (1999) Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamide in bovine retina. Arch Biochem Biophys 370, 300–307.
22Eckardt K, Sell H, Taube A, et al. (2009) Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 52, 664–674.
23Balvers MG, Verhoeckx KC, Plastina P, et al. (2010) Docosahexaenoic acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl ethanolamines with anti-inflammatory properties. Biochim Biophys Acta 1801, 1107–1114.
24Plastina P, Meijerink J, Vincken J-P, et al. (2009) Selective synthesis of unsaturated N-acylethanolamines by lipase-catalyzed N-acylation of ethanolamine with unsaturated fatty acids. Lett Org Chem 6, 444–447.
25Lupinacci E, Meijerink J, Vincken JP, et al. (2009) Xanthohumol from hop (Humulus lupulus L.) is an efficient inhibitor of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha release in LPS-stimulated RAW264.7 mouse macrophages and U937 human monocytes. J Agric Food Chem 57, 7274–7281.
26Green LC, Wagner DA & Glogowski J (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126, 131–138.
27Calder PC (2009) Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 91, 791–795.
28Svennerholm L (1968) Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res 9, 570–579.
29Umhau JC, Zhou W, Carson RE, et al. (2009) Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J Lipid Res 50, 1259–1268.
30Wall KM, Diersen-Schade D & Innis SM (1994) Plasma and tissue lipids of piglets fed formula containing saturated fatty acids from medium-chain triglycerides with or without fish oil. Am J Clin Nutr 59, 1317–1324.
31Dallaire P, Bellmann K, Laplante M, et al. (2008) Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism. Diabetes 57, 1999–2011.
32Kuhlencordt PJ, Chen J, Han F, et al. (2001) Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 103, 3099–3104.
33Ponnuswamy P, Ostermeier E, Schrottle A, et al. (2009) Oxidative stress and compartment of gene expression determine proatherosclerotic effects of inducible nitric oxide synthase. Am J Pathol 174, 2400–2410.
34Jobgen WS, Fried SK, Fu WJ, et al. (2006) Regulatory role for the arginine–nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 17, 571–588.
35Bogdan C (2001) Nitric oxide and the immune response. Nat Immunol 2, 907–916.
36Weldon SM, Mullen AC, Loscher CE, et al. (2007) Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 18, 250–258.
37Sun YX, Tsuboi K, Zhao LY, et al. (2005) Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 1736, 211–220.
38Boring L, Gosling J, Cleary M, et al. (1998) Decreased lesion formation in CCR2− / − mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894–897.
39Gu L, Okada Y, Clinton SK, et al. (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2, 275–281.
40Kanda H, Tateya S, Tamori Y, et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116, 1494–1505.
41Tateya S, Tamori Y, Kawaguchi T, et al. (2010) An increase in the circulating concentration of monocyte chemoattractant protein-1 elicits systemic insulin resistance irrespective of adipose tissue inflammation in mice. Endocrinology 151, 971–979.
42Zhang M & Fritsche KL (2004) Fatty acid-mediated inhibition of IL-12 production by murine macrophages is independent of PPARgamma. Br J Nutr 91, 733–739.
43Mickleborough TD, Tecklenburg SL, Montgomery GS, et al. (2009) Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells. Clin Nutr 28, 71–77.
44Shi Y & Pestka JJ (2009) Mechanisms for suppression of interleukin-6 expression in peritoneal macrophages from docosahexaenoic acid-fed mice. J Nutr Biochem 20, 358–368.
45Schmitz G & Ecker J (2008) The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 47, 147–155.
46Serhan CN, Chiang N & Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349–361.
47Woodward DF, Carling RWC, Cornell CL, et al. (2008) The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther 120, 71–80.
48White PJ & Marette A (2006) Is omega-3 key to unlocking inflammation in obesity? Diabetologia 49, 1999–2001.
49Watanabe S, Doshi M & Hamazaki T (2003) n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 69, 51–59.
50Batetta B, Griinari M, Carta G, et al. (2009) Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 139, 1495–1501.
51Bisogno T, Melck D, De Petrocellis L, et al. (1998) Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 248, 515–522.
52Banni S & Di Marzo V (2010) Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. Mol Nutr Food Res 54, 82–92.
53Grundy SM (2006) Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5, 295–309.
54Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444, 860–867.
55Nathan C (2008) Epidemic inflammation: pondering obesity. Mol Med 14, 485–492.
56Shoelson SE, Lee J & Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116, 1793–1801.
57Elizalde M, Rydén M, Van Harmelen V, et al. (2000) Expression of nitric oxide synthases in subcutaneous adipose tissue of nonobese and obese humans. J Lipid Res 41, 1244–1251.
58Fujimoto M, Shimizu N, Kunii K, et al. (2005) A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 54, 1340–1348.
59Engeli S, Janke J, Gorzelniak K, et al. (2004) Regulation of the nitric oxide system in human adipose tissue. J Lipid Res 45, 1640–1648.
60Sugita H, Kaneki M, Tokunaga E, et al. (2002) Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. Am J Physiol Endocrinol Metab 282, E386–E394.
61Philip CC (2008) Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 52, 885–897.